The prognosis for patients with ST-segment elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) is improved with the use of percutaneous coronary intervention (PCI). Choosing the best procedural anticoagulation regimen to balance the risks of ischemia and bleeding during PCI is essential to optimize outcomes. Heparin, a nonspecific indirect thrombin inhibitor, was the only anticoagulant agent used during PCI for several decades, first with aspirin alone and then with aspirin plus a platelet P2Y₁₂ receptor inhibitor (ticlopidine or clopidogrel). Adding a platelet glycoprotein IIb/IIIa receptor inhibitor to heparin therapy further reduced the risk of stent thrombosis, reinfarction, and death among patients . . .

中文翻译：

---

心肌梗死的程序性抗凝治疗

经皮冠状动脉介入治疗（PCI）可改善ST段抬高型心肌梗死（STEMI）和非STEMI（NSTEMI）患者的预后。选择最佳的程序性抗凝方案以平衡PCI期间缺血和出血的风险对于优化结果至关重要。肝素是一种非特异性的间接凝血酶抑制剂，数十年来一直是PCI期间使用的唯一抗凝剂，首先是单独使用阿司匹林，然后是阿司匹林加血小板P2Y ₁₂受体抑制剂（噻氯匹定或氯吡格雷）。在肝素治疗中添加血小板糖蛋白IIb / IIIa受体抑制剂可进一步降低患者发生支架血栓，再梗塞和死亡的风险。。。